Real-time Estimate
Cboe BZX
09:30:16 2024-05-24 am EDT
5-day change
1st Jan Change
1.41
USD
-2.08%
+3.23%
-31.43%
Presentation Operator MessageOperator (Operator)Good day, and welcome to the Personalis First ...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transcript : Personalis, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08
Earnings Flash (PSNL) PERSONALIS Reports Q1 Revenue $19.5M, vs. Street Est of $18.4M
May. 08
MT
Personalis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 08
CI
Personalis, Inc. Provides Earnings Guidance for the Second Quarter of 2024
May. 08
CI
Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024
May. 08
CI
Lake Street Starts Personalis With Buy Rating, $4 Price Target
Apr. 30
MT
Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring
Mar. 26
CI
Needham Raises Price Target on Personalis to $3.50 From $2.30, Maintains Buy Rating
Feb. 29
MT
Transcript : Personalis, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Feb. 28
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 28
CI
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M
Feb. 28
MT
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024
Feb. 28
CI
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 28
CI
Personalis to Offer ClearNote's Epigenomic Platform in Partnership
Jan. 30
MT
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology
Jan. 30
CI
Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay
Jan. 16
CI
Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023
Jan. 05
CI
Personalis, Tempus Labs to Collaborate on NeXT Personal Dx Detection Test
Nov. 28
MT
Personalis and Tempus Enter into Strategic Collaboration to Advance Cancer Testing
Nov. 28
CI
Myriad Genetics, Personalis Collaborate to Market ImmunoID NeXT Platform
Nov. 16
MT
Myriad Genetics, Inc. and Personalis, Inc. Partner to Market Solutions to Pharma Customers
Nov. 16
CI
Needham Cuts Price Target on Personalis to $2.30 From $7, Maintains Buy Rating
Nov. 08
MT
Transcript : Personalis, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
Personalis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Earnings Flash (PSNL) PERSONALIS Posts Q3 Revenue $18.2M, vs. Street Est of $17M
Nov. 07
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
More about the company
Last Close Price
1.44
USD
Average target price
4.6
USD
Spread / Average Target
+219.44%
Consensus
1st Jan change
Capi.
-31.43% 74.79M +64.92% 62.86B -1.85% 41.38B +45.32% 40.38B -8.93% 27.64B +13.05% 26.46B -21.96% 18.9B +4.21% 12.67B +25.74% 12.27B +27.42% 12.07B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1